title: Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma.
abstract: We analyzed the expression of proteases and the clinicopathologic significance in non-skull base chordoma (NSBC). By using immunohistochemical techniques, we studied the expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B (CatB), and urokinase plasminogen activator (uPA) in 29 NSBCs and compared these data with clinicopathologic parameters and the expression of cell differentiation markers. Expression of MMP-1 (P = .092), MMP-2 (P = .041), and CatB (P = .058) was associated with nuclear pleomorphism, a previously described adverse prognostic indicator. Expression of cytokeratin 8 correlated with that of MMP-1 (P = .005), MMP-2 (P = .002), and uPA (P = .032). Patients with higher MMP-2 expression had a poorer prognosis than those with lower MMP-2 expression (P = .013). We believe that NSBCs with nuclear pleomorphism or stronger epithelial character have a higher invasive ability than those without. In addition, high MMP-2 expression was an indicator of an unfavorable clinical outcome in NSBC.
authors.affiliation: Department of Pathology, Faculty of Medicine, Magdeburg University, Magdeburg, Germany.
authors.forename: Takahiko
authors.initials: T
authors.lastname: Naka
authors.forename: Carsten
authors.initials: C
authors.lastname: Boltze
authors.forename: Doerthe
authors.initials: D
authors.lastname: Kuester
authors.forename: Torss-Oliver
authors.initials: TO
authors.lastname: Schulz
authors.forename: Amir
authors.initials: A
authors.lastname: Samii
authors.forename: Christian
authors.initials: C
authors.lastname: Herold
authors.forename: Helmut
authors.initials: H
authors.lastname: Ostertag
authors.forename: Albert
authors.initials: A
authors.lastname: Roessner
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D002401:Cathepsin B / Q000096:biosynthesis*; D002817:Chordoma / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000378:metabolism; D020782:Matrix Metalloproteinases / Q000096:biosynthesis*; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D014568:Urokinase-Type Plasminogen Activator / Q000096:biosynthesis*
chemical_list: D007633:Keratins; D014568:Urokinase-Type Plasminogen Activator; D002401:Cathepsin B; D020782:Matrix Metalloproteinases